Perspective Therapeutics (NYSEAMERICAN:CATX) Stock: Insider Markus Puhlmann Purchases 35,000 Shares

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) insider Markus Puhlmann purchased 35,000 shares of the stock in a transaction dated Thursday, November 12th. The shares were acquired at an average price of $0.84 per share, for a total transaction of $29,400.00. Following the acquisition, the insider directly owned 178,542 shares of the company’s stock, valued at $149,975.28. This represents a 24.38% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Markus Puhlmann also recently made the following trade(s):

• On Wednesday, November 11th, Markus Puhlmann purchased 6,000 shares of Perspective Therapeutics stock. The shares were acquired at an average cost of $0.83 per share, for a total transaction of $4,980.00.

Perspective Therapeutics Stock Up 2.1%

Shares of Perspective Therapeutics stock opened at $0.84 on Friday. The stock has a 50-day moving average price of $2.15 and a 200 day moving average price of $3.45. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 6.61. Perspective Therapeutics, Inc. has a 1 year low of $0.78 and a 1 year high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). Perspective Therapeutics had a negative return on equity of 42.25% and a negative net margin of 55,866.82%. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. On average, research analysts expect that Perspective Therapeutics, Inc. will post -1.01 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Provenance Wealth Advisors LLC purchased a new stake in shares of Perspective Therapeutics during the 3rd quarter worth about $44,000. Auctus Advisors LLC lifted its holdings in shares of Perspective Therapeutics by 83.6% during the 3rd quarter. Auctus Advisors LLC now owns 37,359 shares of the company’s stock valued at $103,000 after buying an additional 17,015 shares during the last quarter. Russell Investments Group Ltd. grew its stake in shares of Perspective Therapeutics by 53.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company’s stock valued at $168,000 after buying an additional 21,150 shares in the last quarter. Quantinno Capital Management LP bought a new stake in shares of Perspective Therapeutics in the 1st quarter valued at approximately $273,000. Finally, Taylor & Morgan Wealth Management LLC grew its stake in shares of Perspective Therapeutics by 127.6% in the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company’s stock valued at $225,000 after buying an additional 37,000 shares in the last quarter. 54.66% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

CATX has been the subject of a number of research analyst reports. Piper Sandler reduced their price target on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. BMO Capital Markets reiterated an “outperform” rating on shares of Perspective Therapeutics in a research note on Friday, October 30th. Wedbush reiterated an “outperform” rating and issued a $7.00 target price (down from $9.00) on shares of Perspective Therapeutics in a research report on Tuesday. Bank of America decreased their target price on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research note on Friday, August 14th. Finally, BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a report on Monday, October 26th. Nine equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $10.10.

Perspective Therapeutics Company Profile

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.